Similar articles

• Effect of BCG treatment on the evolution of cell-mediated immunity in mice bearing transplantable syngeneic tumors.

  Youn JK, Francois DL, Santillana M, Hue G, Barski G. Youn JK, et al. Eur J Cancer (1965). 1977 Feb;13(2):177-86. doi: 10.1016/0014-2964(77)90197-9. Eur J Cancer (1965). 1977. PMID: 852489 No abstract available.
• Inhibition or enhancement of rat mammary tumors dependent on dose BCG.

  Piessens WF, Campbell M, Churchill WH. Piessens WF, et al. J Natl Cancer Inst. 1977 Jul;59(1):207-11. doi: 10.1093/jnci/59.1.207. J Natl Cancer Inst. 1977. PMID: 875054
• Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.

  Purnell DM, Bartlett GL, Kreider JW, Biro TG. Purnell DM, et al. Cancer Res. 1977 Apr;37(4):1137-40. Cancer Res. 1977. PMID: 844041
• Spontaneous murine mammary adenocarcinoma: model system for evaluation of combined methods of therapy.

  Stolfi RL, Martin DS, Fugmann RA. Stolfi RL, et al. Cancer Chemother Rep. 1971 Jun;55(3):239-51. Cancer Chemother Rep. 1971. PMID: 4329953 Review. No abstract available.
• Immunologic therapies of kidney carcinoma.

  McCune CS. McCune CS. Semin Oncol. 1983 Dec;10(4):431-6. Semin Oncol. 1983. PMID: 6198729 Review. No abstract available.